Omeros Launches First Commercial Sales of YARTEMLEA for Rare Transplant Complication
Event summary
- Omeros began commercial shipments of YARTEMLEA® for stem cell transplant-associated thrombotic microangiopathy (TA-TMA) on January 20, 2026.
- The drug is the first and only FDA-approved therapy for TA-TMA, targeting a rare but often-fatal complication in both adults and children aged two and older.
- YARTEMLEA inhibits MASP-2, blocking the lectin pathway of complement while preserving other immune functions.
- Approximately 30,000 allogeneic stem cell transplants occur annually in the U.S. and Europe, with TA-TMA affecting up to 56% of recipients.
The big picture
Omeros' launch of YARTEMLEA marks a significant milestone in treating TA-TMA, a severe complication of stem cell transplants with limited therapeutic options. The drug’s selective inhibition of the lectin pathway positions it as a potential standard of care, though its success will depend on adoption rates among transplant centers and regulatory approvals in key markets like Europe.
What we're watching
- Regulatory Approval
- Whether the European Medicines Agency (EMA) will approve YARTEMLEA for TA-TMA by mid-2026, expanding its commercial reach.
- Market Penetration
- The pace at which Omeros can capture market share in a niche but high-mortality indication like TA-TMA.
- Pipeline Progress
- How the success of YARTEMLEA will influence the development and commercialization of Omeros’ other pipeline assets, including OMS1029 and OMS527.
Our editorial coverage:
Related topics